Abivax Reports Third Quarter 2025 Financial Results

Abivax, a biotechnology company in Paris, announced financial results for Q3 2025, highlighting a cash position of EUR 589.7 million as of September 30, 2025, sufficient to fund operations into the fourth quarter of 2027. Operating losses increased to EUR 174.4 million, driven by heightened research and development (R&D) expenses, which rose by EUR 25.4 million. This was largely due to its ongoing phase 3 trials in ulcerative colitis and Crohn's disease.

General and administrative costs also increased by EUR 16.5 million. Financial losses reached EUR 79.7 million, primarily affected by changes in the fair value of convertible notes and foreign exchange losses. The company's net loss for the period was EUR 254.1 million. Despite the loss, the company's cash position was bolstered by a public offering in July 2025, generating net proceeds of approximately EUR 597.2 million.